BofA raised the firm’s price target on BeiGene to $200 from $180.18 and keeps a Neutral rating on the shares. The firm raised its revenue forecast for 2023 and beyond given the “robust product sales” seen in Q3, but reiterates a Neutral rating as it argues that the company’s on-track international development on its pipeline has to be balanced against price cut risks in China’s domestic market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BGNE:
- BeiGene reports Q3 EPS $2.01, consensus ($3.09)
- BGNE Upcoming Earnings Report: What to Expect?
- Adaptive Biotechnologies announces new collaboration with BeiGene
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- BeiGene price target lowered to $222 from $304 at TD Cowen
Questions or Comments about the article? Write to editor@tipranks.com